New combo therapy tested to delay insulin need in early diabetes
NCT ID NCT06338553
Summary
This study is testing if adding a GLP-1 drug (like semaglutide) to the immunotherapy teplizumab can better manage early-stage Type 1 diabetes. Researchers will give 24 participants a liquid meal and measure their blood sugar, insulin response, and blood vessel health after taking either the GLP-1 drug or a placebo. The goal is to see if this combination can help control blood sugar levels and improve heart health, potentially delaying the need for insulin injections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.